Fananserin (RP-62203) is a drug which acts as a potent antagonist at both the 5HT 2A receptor, [1] and the Dopamine D 4 receptor, [2] but without blocking other dopamine receptors such as …

Design, synthesis and molecular modelling of new bulky Fananserin derivatives with altered pharmacological profile as potential antidepressants

Fananserin | C23H24FN3O2S | CID 60785 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity …

1996年10月24日 · Fananserin, thus, offers an original in vitro profile of monoamine receptor binding, high affinity for D4 and 5-HT2A receptors and low affinity for dopamine D2 recep- tors. …

Objective: The authors' objective was to assess the potential efficacy of fananserin (RP62203), a potent antagonist at the D4 and serotonin2A (5-HT2A) receptors, on symptoms of …

Fananserin (RP 62203) is an orally bioavailable, potent and selective 5-hydroxytryptamine2 (5-HT 2) receptor antagonist, with a K i of 0.37 nM for the rat 5-HT 2A receptor. Fananserin also is a …

2019年8月1日 · The aim of the study was to synthesize a bulky derivatives of Fananserin, with an altered pharmacological profile. We have focused on the search for multifunctional ligands for …

1996年10月24日 · This report describe the affinity of the 5-HT2A receptor antagonist RP 62203 (fananserin) for the human dopamine D4 receptor. Fananserin displaces [3H]spiperone …

法南色林是由赛诺菲研发的一种小分子药物，是一种drd4拮抗剂和5-ht2a拮抗剂。目前该药物最高研发阶段为无进展，用于治疗重度抑郁症、焦虑和精神分裂症。